Genome-scale CRISPR-Cas9 screen reveals novel regulators of B7-H3 in tumor cells.

Shasha ZhaoYuelong WangNian YangMin MuZhiguo WuHexian LiXin TangKunhong ZhongZongliang ZhangCheng HuangTing CaoMeijun ZhengGuoqing WangChunlai NieHui YangGang GuoLiangxue ZhouXi ZhengAiping Tong

Published in: Journal for immunotherapy of cancer (2022)

Activation of p38 MAPK-eIF4E signaling serves as a key event in the transcription initiation and B7-H3 protein expression in tumor cells. Genetically targeting SP20H upregulates target antigen expression and sensitizes tumors to anti-B7-H3 treatment. Collectively, our findings provide new insight into the mechanisms underlying B7-H3 expression and introduce a potential synergistic target for existing antibody-based targeted therapy against B7-H3.

Keyphrases

poor prognosis
crispr cas
genome editing
transcription factor
cancer therapy
long non coding rna
gene expression
oxidative stress
induced apoptosis
combination therapy
dna methylation
smoking cessation